Lakefront Biotherapeutics NV LKFT

LKFT Company Overview

Galapagos NV is a clinical-stage biotechnology company focused on the discovery and development of innovative medicines, with a strategic emphasis on oncology and immunology. The company historically operated across small-molecule drug discovery and development, but since 2023 it has pivoted toward cell therapy–based oncology platforms following a broad strategic reset. Galapagos does not currently generate material recurring commercial revenue and primarily operates as a research and development organization.

The company was founded in 1999 by Onno van de Stolpe and built its early reputation in target discovery and small-molecule drug development, most notably through its long-standing collaboration with Gilead Sciences. Its lead product, filgotinib (Jyseleca), achieved approval in Europe and Japan for inflammatory diseases, but commercial rights and collaboration economics were later restructured. Beginning in 2022–2023, Galapagos redirected its capital and operations toward oncology, leveraging a strong balance sheet and divesting or discontinuing non-core programs.